Fig. 6
Low PAPSS1 and high ERα associated with improved OS, PFS and cisplatin-sensitivity in ovarian cancer patients. A Kaplan–Meier plots of overall survival and PFS in OC patients stratified according to their PAPSS1 (P = 0.025, log-rank test) and ESR1 (P = 0.00045, log-rank test) status. The side panel on the right in Fig. 6A illustrates a median survival time for PFS and OS comparison of ESR1 and PAPSS1 expression in ovarian cancer patients. B Kaplan–Meier plots of overall survival and PFS in OC patients for which platin-based chemotherapy stratified according to their PAPSS1 (P = 0.045, log-rank test) and ESR1 (P = 0.000027, log-rank test) status. The panel at the bottom in Fig. 6B illustrates a median survival time for PFS and OS comparison of ESR1 and PAPSS1 expression in platin-based chemotherapy ovarian cancer patients. C Data from TCGA showed that ESR1 has a high expression level in ovarian cancer tissues (ovarian cancer n = 426 and normal ovarian tissues n = 88) (*P < 0.05). The red is tumor tissue and grey is normal tissue. D IHC staining shows lower ERα and higher PAPSS1 expression in platinum-resistant OC specimens than in non-resistant specimens. The IHS of PAPSS1 and ESR1 in the OC tissue assay are summarized as the normalized means of scores ± standard error (SE) on the right side in D (**P < 0.01). Scale bar: 100 µm. E Relatively expression of PAPSS1 and ESR1 mRNA in OC tumor platinum resistance and platinum-sensitive specimens by beeswarm plot (**P < 0.01). F ROC curves and boxplots of PAPSS1 and ESR1 in ovarian cancer patients undergoing platinum treatment for relapse-free survival time of 6 months. Area under curve (AUC); TNR true negative rate (TNR); true positive rate (TPR) (http://www.rocplot.org/, accessed on October 2021)